Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Pfizer”

Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)Terminated
NCT03642132Phase 3Updated Apr 6, 2023
Sponsor: Pfizer
Ovarian Cancer
United States, Australia, Belgium, Ireland, Italy +5 more
Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.Completed
NCT04033991N/AUpdated Apr 6, 2023
Sponsor: Pfizer
Carcinoma · Renal Cell
United Kingdom
Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan).Completed
NCT00716820N/AUpdated Apr 6, 2023
Sponsor: Pfizer
Gastrointestinal Stromal Tumors
Non-interventional, Retrospective Cohort Study to Explore OAC Treatment in KoreaCompleted
NCT03572972N/AUpdated Apr 6, 2023
Sponsor: Pfizer
Atrial Fibrillation
South Korea
Sedation Of Adult Patients Undergoing Gastrointestinal Endoscopy: A Network Meta-analysisCompleted
NCT03632330N/AUpdated Apr 6, 2023
Sponsor: Pfizer
Gastrointestinal Endoscopy · Sedation · Dexmedetomidine
South Korea
Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line SunitinibCompleted
NCT04076787N/AUpdated Apr 6, 2023
Sponsor: Pfizer
Metastatic Renal Cell Carcinoma
Canada
Burden of Disease Study In Patients With Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP) orTransthyretin Cardiomyopathy (TTR-CM) And CaregiversCompleted
NCT01604122N/AUpdated Apr 6, 2023
Sponsor: Pfizer
Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP) · Transthyretin Cardiomyopathy (TTR-CM) · Familial Amyloid Cardiomyopathy · Senile Systemic Amyloidosis (SSA)
Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.Completed
NCT04647110N/AUpdated Apr 6, 2023
Sponsor: Pfizer
ALK-positive NSCLC
Sweden
Serotype Distribution of Streptococcus Pneumoniae That Causes Invasive Diseases at Children and Adults in TurkeyCompleted
NCT01810861N/AUpdated Apr 6, 2023
Sponsor: Pfizer
Pneumococcal Diseases
Turkey (Türkiye)
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis FungoidesTerminated
NCT02890368Phase 1Updated Apr 5, 2023
Sponsor: Pfizer
Solid Tumors · Mycosis Fungoides · Melanoma · Merkel-cell Carcinoma
United States
NOAC Portuguese Real World StudyWithdrawn
NCT04808934N/AUpdated Apr 5, 2023
Sponsor: Pfizer
Stroke · Systemic Embolism · Major Bleeding
Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme BorreliosisCompleted
NCT03010228Phase 1Updated Apr 5, 2023
Sponsor: Pfizer
Lyme Borreliosis, Nervous System
United States, Belgium
Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer PatientsCompleted
NCT00432172Phase 2Updated Apr 3, 2023
Sponsor: Spanish Breast Cancer Research Group
Breast Cancer
Spain
Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant MelanomaTerminated
NCT03878719Phase 1Updated Apr 3, 2023
Sponsor: Pfizer
Melanoma
Italy
EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast CancerCompleted
NCT00129935Phase 3Updated Mar 31, 2023
Sponsor: Spanish Breast Cancer Research Group
Breast Cancer
Spain
Decitabine and Talazoparib in Untreated AML and R/R AMLCompleted
NCT02878785Phase 1, Phase 2Updated Mar 29, 2023
Sponsor: University of Maryland, Baltimore
Acute Myeloid Leukemia
United States
Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients Diagnosed With HR+/HER2 Advanced/Metastatic Breast Cancer on Palbociclib + Aromatase Inhibitor (AI) Combination TherapyCompleted
NCT04394247N/AUpdated Mar 21, 2023
Sponsor: Pfizer
Breast Cancer
United States
A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable RemissionTerminated
NCT03281304Phase 4Updated Mar 21, 2023
Sponsor: Pfizer
Ulcerative Colitis
United States, Belgium, Canada, Czechia, France +15 more
UK Ibrance Patient Program (IPP) StudyCompleted
NCT03921866N/AUpdated Mar 17, 2023
Sponsor: Pfizer
HR+/HER2- Locally Advanced, Metastatic Breast Cancer
United Kingdom
Clinical Outcome Of Advanced Renal Cell Carcinoma In TaiwanCompleted
NCT02776644N/AUpdated Mar 16, 2023
Sponsor: Pfizer
Renal Cell Carcinoma
Effect of Vaginal Estrogen on Asymptomatic Microhematuria (AMH)Terminated
NCT02213757Phase 4Updated Mar 15, 2023
Sponsor: Medstar Health Research Institute
Microscopic Hematuria
United States
Feasibility of an Individualized Goals of Care Discussion Guide for Advanced Breast CancerCompleted
NCT03375827NAUpdated Mar 14, 2023
Sponsor: Massachusetts General Hospital
Breast Cancer
United States
Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or FulvestrantCompleted
NCT02894398Phase 2Updated Mar 13, 2023
Sponsor: iOMEDICO AG
Breast Cancer · Hormone Receptor Positive Tumor · Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Germany
Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to FulvestrantCompleted
NCT03447132Phase 3Updated Mar 10, 2023
Sponsor: International Cancer Research Group, United Arab Emirates
Breast Neoplasm Female
Algeria, Egypt, Jordan, Lebanon, Morocco +3 more
Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast CancerCompleted
NCT03969121Phase 3Updated Mar 10, 2023
Sponsor: Kyoto Breast Cancer Research Network
Breast Cancer Female · Hormone Receptor Positive Malignant Neoplasm of Breast
Australia, Hong Kong, Japan, South Korea, Taiwan

Previous page Next page